Programmed Death Ligand-1 Blocker
- Name
- Programmed Death Ligand-1 Blocker
- Accession Number
- DBCAT003819
- Description
Not Available
- Drugs
Drug Drug Description Durvalumab An antineoplastic monoclonal antibody used to treat urothelial carcinoma and locally advanced, unresectable non-small cell lung cancer. Avelumab An anti-PD-L1 monoclonal antibody used to treat metastatic merkel cell carcinoma, metastatic urothelial carcinoma, or renal cell carcinoma. - Drugs & Drug Targets
Drug Target Type Durvalumab Programmed cell death 1 ligand 1 target Durvalumab Programmed cell death protein 1 target Avelumab Programmed cell death 1 ligand 1 target